CTOs on the Move


 
At DocRX we help doctors and hospitals become more efficient, and profitable. We also help make them compliant with regulations. Visit us today!
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.docrx.com
  • 4636, Bit and Spur Road
    Mobile, AL USA 36608
  • Phone: 877.362.7991

Executives

Name Title Contact Details

Similar Companies

Ascentage Pharma

Ascentage Pharma is a globally-focused, clinical-stage biopharmaceutical company developing novel small molecule therapies for cancers, hepatitis B and age-related diseases. Based on breakthrough technology from the University of Michigan, the Company`s expertise is in designing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death, in cancers. Ascentage has built a rich pipeline of six clinical candidates, including a novel, highly potent Bcl-2/Bcl-xL inhibitor, APG-1252, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors.

Osta Biotechnologies

Osta Biotechnologies Inc. is a Dollard-Des-Ormeaux, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Shasun USA Inc

Shasun USA Inc is a Piscataway, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

OVP HEALTH

HEALTHIER. COMMUNITY. OVP HEALTH provides an extensive range of addiction treatment services, emergency department and hospitalist staffing and management services.

La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has four product candidates in development. LJPC-501 is La Jolla’s proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension and hepatorenal syndrome. GCS-100 is La Jolla’s first-in-class galectin-3 inhibitor for the potential treatment of chronic kidney disease. LJPC-1010, La Jolla’s second-generation galectin-3 inhibitor, is a more potent and purified derivative of GCS-100 that can be delivered orally for the potential treatment of nonalcoholic steatohepatitis and other diseases characterized by tissue fibrosis. LJPC-401 is La Jolla’s novel formulation of hepcidin for the potential treatment of conditions characterized by iron overload, such as hemochromatosis and beta thalassemia